While JAK2 inhibitors are approved for use in intermediate-2 or high-risk myelofibrosis (MF), there are inadequate treatments for patients in early disease stages. Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the results of a pilot study of ropeginterferon, an inferon alpha cytokine therapy, in MF patients. Ropeginterferon was trialed in cohorts of early disease and advanced disease patients, based on a reduced clonal burden seen in chronic myelogenous leukemia and polycythemia vera with the use of cytokine therapy. The results show that the treatment was well-tolerated and may be of clinical benefit to MF patients. These initial findings support the ongoing investigation into ropeginterferon in myelofibrosis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

свернуть